دانلود کتاب Tumor Suppressing Viruses, Genes, and Drugs: Innovative Cancer Therapy Approaches

فهرست مطالب :

Front Cover......Page 1
Tumor-Suppressing Viruses, Genes, and Drugs......Page 4
Contents......Page 6
Contributors......Page 12
Preface......Page 16
Chapter 1. Oncolytic Viruses: Virotherapy for Cancer......Page 17
I. Introduction......Page 18
III. Approaches to Optimizing Tumor-Selective Viral Replication......Page 20
IV. Adenoviruses......Page 21
V. Poliovirus......Page 23
VII. Reovirus......Page 24
VIII. Bacteria......Page 25
IX. Vaccinia Virus......Page 26
X. Herpesvirus......Page 28
XI. Clinical Trial Results with Replication-Competent Adenoviruses in Cancer Patients......Page 32
XII. Results from Clinical Trials with dl1520 (Onyx-015, or CI-1042)......Page 35
XIII. Future Directions: Approaches to Improving the Efficacy of Replication-Selective Viral Agents......Page 39
References......Page 40
I. Introduction......Page 47
II. Reovirus Oncolysis......Page 50
III. Concluding Remarks......Page 56
References......Page 57
I. Introduction......Page 61
II. Preclinical Studies of G207......Page 64
III. G207 Clinical Trial......Page 81
IV. Conclusions......Page 83
References......Page 84
I. Introduction......Page 93
II. Activation of p53......Page 94
III. Downstream Mediators of p53......Page 97
References......Page 106
I. Introduction......Page 113
II. Functions of RB......Page 116
III. Successes with RB Gene Therapy......Page 126
IV. Perspectives......Page 129
References......Page 131
I. Introduction......Page 139
II. G1 Regulation......Page 140
III. p16INK4a and the Rb Pathway......Page 147
IV. p19ARF and p53 Pathway......Page 149
V. p27 and Human Cancer......Page 151
VI. Conclusions and Future Perspectives......Page 152
References......Page 153
I. Introduction......Page 161
II. Cyclin-Dependent Kinases, the Cell Cycle, and Cancer......Page 162
III. Cyclin-Dependent Kinase Inhibitors, a Large Variety of Structures......Page 165
IV. Cyclin-Dependent Kinase Inhibitors, All Competing with ATP......Page 167
V. Cyclin-Dependent Kinase Inhibitors, the Selectivity Problem......Page 168
VI. Cyclin-Dependent Kinase Inhibitors, Cellular Effects......Page 170
VII. Cyclin-Dependent Kinase Inhibitors, Antitumor Activity......Page 171
VIII. Conclusion......Page 177
References......Page 178
I. RAS Molecules: Normal versus Oncogenic Mutants......Page 185
II. Super GAP?......Page 186
III. RAS-Binding Fragment of NF1......Page 187
IV. c-RAF-1......Page 188
VI. Ral GDS......Page 189
References......Page 190
I. Introduction (Historical Background)......Page 193
II. Type I Cytoskeletal Tumor Suppressors......Page 195
III. Type II Cytoskeletal Tumor Suppressors......Page 202
References......Page 208
I. Introduction......Page 215
III. TGF-β Superfamily Signaling......Page 216
IV. Perturbation of TGF-β Signaling in Cancer Cells......Page 223
V. Perspectives......Page 228
References......Page 229
I. Introduction......Page 237
II. Cloning of DAN cDNA......Page 238
IV. Role of DAN in Neuroblastomas......Page 239
V. Structural Features of the DAN Protein......Page 241
VII. DAN Family......Page 244
References......Page 247
I. Introduction......Page 249
II. Ribozyme Expression System in Cells......Page 252
III. Design of the tRNAVal-Driven Ribozyme That Is Transcribed by pol III......Page 256
IV. Design of Allosterically Controlled Maxizymes......Page 262
V. Conclusion......Page 271
References......Page 272
I. Introduction—Angiogenesis......Page 277
II. Angiogenesis Inhibitors......Page 281
III. Future Directions......Page 290
References......Page 292
I. Introduction......Page 309
III. Ras Is Not a Crucial Target of Farnesyltransferase Inhibitors......Page 310
IV. RhoB Is a Crucial Target of Farnesyltransferase Inhibitors......Page 311
V. Farnesyltransferase Inhibitors Act through a Gain of Function Mechanism Involving RhoB-GG......Page 313
VI. RhoB-GG Is Required to Mediate Apoptosis by Farnesyltransferase Inhibitors......Page 314
VIII. Clinical Implications......Page 318
IX. Summary......Page 320
References......Page 321
I. Introduction......Page 327
II. Ras Cycle and Ras–Raf Signaling Pathway......Page 328
III. The Structure of Ras Proteins......Page 329
IV. Drug Target Sites of Ras......Page 331
References......Page 339
I. Introduction......Page 345
II. MKT-077: F-Actin Bundler......Page 346
III. Chaetoglobosin K: F-Actin Capper......Page 350
References......Page 354
I. Introduction......Page 357
II. Tyr Kinase Inhibitors......Page 360
III. Chronic Myelogenous Leukemia......Page 361
IV. Epidermal Growth Factor Receptor......Page 362
V. Antagonists of the Epidermal Growth Factor Receptor Extracellular Domain......Page 363
VI. Chemical Inhibitors of the Kinase Domain of the Epidermal Growth Factor Receptor......Page 364
VII. Epidermal Growth Factor Receptor Antagonists or Inhibitors Act Synergistically to Kill Tumor Cells......Page 366
VIII. The Effects of Abl Inhibitors on Leukemia......Page 368
References......Page 370
I. Rho Family GTPases (Rho, Rac, and CDC42)......Page 377
II. Blocking PAKs......Page 378
III. Blocking CDC42 Pathways (ACKs and N-WASP)......Page 386
IV. Blocking Rho Pathways......Page 388
V. Rac-Specific Inhibitors?......Page 390
References......Page 391
I. Introduction......Page 395
II. Signaling Pathways Activated by Integrins......Page 397
III. Role of Integrins in Neoplastic Transformation......Page 400
IV. Role of Integrins in Tumor-Induced Angiogenesis......Page 401
V. Integrin Antagonists as Antiangiogenesis Agents......Page 404
VI. Conclusions and Future Perspectives......Page 407
References......Page 408
I. Introduction......Page 413
II. Multiple Pathways of p53-Induced Apoptosis......Page 414
III. Regulation of p53 Activity......Page 416
IV. Approaches toward Reactivation of Mutant p53......Page 418
V. Implications for Tumor Therapy and Future Perspectives......Page 424
References......Page 427
Index......Page 433